Cite
HARVARD Citation
Gershenson, D. et al. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 399 (10324), pp. 541-553. [Online].